Combination Therapy with Fenofibrate and Statin

Introduction to Combination Therapy

The American Heart Association recommends combination therapy with fenofibrate and any statin when clinically indicated, due to fenofibrate's favorable safety profile and lack of significant pharmacokinetic interactions 1
Combination therapy with fenofibrate and a statin may be considered in patients with severe hypertriglyceridemia or moderate hypertriglyceridemia with high ASCVD risk, as it may help reduce the risk of acute pancreatitis and improve lipid profiles 1, 2, 3

The American College of Cardiology and American Heart Association suggest that fenofibrate may be added to statin therapy in patients with severe hypertriglyceridemia (≥500 mg/dL) to reduce the risk of acute pancreatitis 2, 3
The American College of Cardiology and American Heart Association recommend considering fenofibrate with a low- or moderate-intensity statin in patients with moderate hypertriglyceridemia and high ASCVD risk, when benefits from ASCVD risk reduction or triglyceride lowering outweigh potential risks 1
Post-hoc analysis of the ACCORD trial suggests potential benefit of combination therapy in men with triglycerides ≥204 mg/dL and HDL cholesterol ≤34 mg/dL, although this remains hypothesis-generating 4, 3

The American Heart Association warns that combination therapy with fenofibrate and a statin increases the risk of myopathy and rhabdomyolysis, particularly in elderly patients and those with diabetes, renal failure, or hypothyroidism, although the risk is significantly lower with fenofibrate compared to gemfibrozil 1
The American College of Cardiology and American Heart Association emphasize the importance of monitoring liver function and renal function in patients on combination therapy, as fenofibrate can increase serum creatinine levels and cause liver injury 5

The American Heart Association advises against combining gemfibrozil with lovastatin, pravastatin, or simvastatin, as this combination is potentially harmful 1

The American College of Cardiology recommends that fenofibrate combined with a statin is not contraindicated and may be considered when the benefits from ASCVD risk reduction or triglyceride lowering outweigh the potential risks, but this combination requires careful patient selection and monitoring, especially in those with renal impairment 6
Gemfibrozil should not be initiated in patients on statin therapy due to significantly increased risk for muscle symptoms and rhabdomyolysis, as recommended by the American College of Cardiology 6

The American College of Cardiology suggests that before initiating fenofibrate with statin, baseline renal function and hepatic transaminases should be obtained, and creatine kinase should be measured 6
The American College of Cardiology recommends adjusting fenofibrate dose if eGFR is 30-59 mL/min/1.73 m², with a maximum dose of 54 mg/day, and implementing mandatory monitoring schedule 6
The American College of Cardiology advises using low- or moderate-intensity statin, not high-intensity, when combining with fenofibrate 6

The American College of Cardiology indicates that combination therapy may be justified for patients with severe hypertriglyceridemia (≥500 mg/dL) or triglycerides ≥204 mg/dL with HDL ≤34 mg/dL 6